Via PR Web
Durham, NC (PRWEB) July 27, 2012
A team of researchers in Japan has discovered that VD3, a super-active form of Vitamin D, boosts stem cells to enhance and maintain their ability to induce hair growth. This new study, reported in STEM CELLS Translational Medicine, builds upon previous studies that have demonstrated how dermal papilla cells (DPCs) can stimulate epithelial stem cells to become hair.
“We had already discovered how VD3 increases the transforming growth factor TGF-ß2 and alkali-phosphatase activity — two essential features of hair-inducing DPCs. This time we focused on VD3’s therapeutic potency and values for hair regeneration,” said Kotaro Yoshimura, M.D. “The results suggest that it may be useful in expanding human DPCs with good quality, and help establish a DPC transplantation therapy for growing hair.”
Yoshimura and Noriyuki Aoi, M.D., both of the University of Tokyo (UT) School of Medicine, led scientists from UT, Osaka University and the Japan Science and Technology Agency in the investigation. After running more tests on how VD3 affected another crucial element for hair growth called Wnt10b gene expression, they collected DPCs from volunteers who had undergone facelifts, incubated the DPCs with VD3 and then grafted them onto hairless skin samples taken from rats.
“We found that treating the dermal papilla cells with VD3 significantly enhanced the growth of new hair over that of the control group,” Dr. Aoi said. “We also observed a better rate of maturation of the follicles. In other words, the hair grew thicker and lasted longer.”
“This study may contribute to the development of a cell-based therapy for hair regeneration,” said Anthony Atala, MD, Editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. “The research team shows the potential impact of vitamin D to boost the capacity of certain cells in the skin to form hair.”
About STEM CELLS Translational Medicine:
STEM CELLS TRANSLATIONAL MEDICINE (SCTM), published by AlphaMed Press, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.
About AlphaMed Press:
Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS® (http://www.StemCells.com), celebrating its 30th anniversary in 2012, is the world’s first journal devoted to this fast paced field of research. The Oncologist® (http://www.TheOncologist.com), also a monthly peer-reviewed publication, entering its 17th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.